New hope for rare bone cancer: experimental combo shows promise

NCT ID NCT05046314

First seen Jan 15, 2026 · Last updated May 16, 2026 · Updated 12 times

Summary

This study tested a new drug called TK216 combined with vincristine in 15 people with Ewing's sarcoma that had come back or stopped responding to treatment. The goal was to see if the combination could shrink tumors or slow the cancer. The trial was completed in China and focused on measuring how many patients responded and how long they lived.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA, EWING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450003, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, 450003, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410031, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, 200233, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • Tianjin Medical University Cancer Institude & Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 100005, China

Conditions

Explore the condition pages connected to this study.